PL2755997T3 - Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7 - Google Patents

Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7

Info

Publication number
PL2755997T3
PL2755997T3 PL12761862T PL12761862T PL2755997T3 PL 2755997 T3 PL2755997 T3 PL 2755997T3 PL 12761862 T PL12761862 T PL 12761862T PL 12761862 T PL12761862 T PL 12761862T PL 2755997 T3 PL2755997 T3 PL 2755997T3
Authority
PL
Poland
Prior art keywords
hla
restricted
cell receptors
recognize mage
mage
Prior art date
Application number
PL12761862T
Other languages
English (en)
Inventor
Paul F. Robbins
Steven A. Rosenberg
Shiqui ZHU
Steven A. FELDMAN
Richard A. Morgan
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of PL2755997T3 publication Critical patent/PL2755997T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL12761862T 2011-09-15 2012-09-11 Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7 PL2755997T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535086P 2011-09-15 2011-09-15
EP12761862.7A EP2755997B1 (en) 2011-09-15 2012-09-11 T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
PCT/US2012/054623 WO2013039889A1 (en) 2011-09-15 2012-09-11 T cell receptors recognizing hla-a1- or hla-cw7-restricted mage

Publications (1)

Publication Number Publication Date
PL2755997T3 true PL2755997T3 (pl) 2019-01-31

Family

ID=46881176

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12761862T PL2755997T3 (pl) 2011-09-15 2012-09-11 Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7
PL18175738T PL3392270T3 (pl) 2011-09-15 2012-09-11 Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18175738T PL3392270T3 (pl) 2011-09-15 2012-09-11 Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7

Country Status (12)

Country Link
US (4) US20140378389A1 (pl)
EP (3) EP3392270B1 (pl)
JP (3) JP6415322B2 (pl)
CN (2) CN103974974A (pl)
AU (2) AU2012309830B2 (pl)
CA (2) CA2848209C (pl)
ES (2) ES2834070T3 (pl)
IL (4) IL290105B2 (pl)
PL (2) PL2755997T3 (pl)
PT (2) PT3392270T (pl)
SI (2) SI2755997T1 (pl)
WO (1) WO2013039889A1 (pl)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101441693B1 (ko) 2005-10-18 2014-09-25 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및사용 방법
SG190661A1 (en) 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
EP3392270B1 (en) 2011-09-15 2020-08-26 The United States of America, as Represented by the Secretary Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
ES2774931T3 (es) 2012-09-14 2020-07-23 Us Health Receptores de linfocitos t que reconocen MAGE-A3 restringida al MHC de clase II
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
CA2963364A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
JP6686008B2 (ja) * 2014-10-02 2020-04-22 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
CN107002043A (zh) * 2014-10-31 2017-08-01 贝勒医学院 靶向肿瘤而非t细胞的存活素特异性t细胞受体
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016176322A1 (en) 2015-04-27 2016-11-03 Abvitro Llc Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
CN108350059B (zh) 2015-09-15 2021-10-08 美国卫生和人力服务部 识别hla-cw8限制性突变kras的t细胞受体
CN114195882A (zh) * 2015-10-01 2022-03-18 圣拉斐尔医院有限公司 Tcr及其用途
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
HRP20211493T1 (hr) 2016-04-08 2022-01-21 Adaptimmune Limited Receptori t stanica
ES2914648T3 (es) 2016-04-08 2022-06-15 Immunocore Ltd Receptores de células T
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
DK3448882T3 (da) * 2016-04-26 2022-02-21 Us Health Anti-kk-lc-1-t-cellereceptorer
US20190324030A1 (en) * 2016-06-27 2019-10-24 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
PL3494133T3 (pl) * 2016-08-02 2022-11-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptory limfocytów t anty-kras-g12d
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US12227578B2 (en) 2016-11-11 2025-02-18 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
WO2018097951A1 (en) 2016-11-22 2018-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3/a6 antibodies
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
PT3551221T (pt) 2016-12-08 2022-01-18 Immatics Biotechnologies Gmbh Novos recetores de células t e imunoterapia empregando os mesmos
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
SI3580561T1 (sl) 2017-02-12 2024-04-30 Biontech Us Inc. Metode, osnovane na hla, in njihove sestave ter uporabe
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
MX2019012398A (es) 2017-04-18 2020-09-25 Broad Inst Inc Composiciones para detectar secreciones y metodos de uso.
EA201992536A1 (ru) * 2017-04-24 2020-03-05 Оспедале Сан Раффаэле С.Р.Л. Tcr и пептиды
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
EP4026554A1 (en) 2017-08-03 2022-07-13 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
KR20200066616A (ko) 2017-09-21 2020-06-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
AU2019209428B2 (en) 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
ES3052818T3 (en) 2018-02-09 2026-01-14 Us Health Tethered interleukin-15 and interleukin-21
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
CA3097399A1 (en) 2018-04-19 2019-10-24 The Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
EP3784774B1 (en) 2018-04-24 2025-11-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
EP3810182A4 (en) 2018-06-19 2022-08-24 BioNTech US Inc. Neoantigens and uses thereof
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
HUE065436T2 (hu) * 2019-01-17 2024-06-28 Immunocore Ltd Kiszerelések
CN120607607A (zh) 2019-01-22 2025-09-09 美国卫生和人力服务部 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CN114072166A (zh) 2019-05-14 2022-02-18 泰加生物工艺学公司 用于治疗t细胞耗竭的组合物和方法
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
EP4100428A4 (en) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and their uses
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for producing engineered memory-like nk cells and preparations containing them
CA3171370A1 (en) * 2020-03-16 2021-09-23 Ugur Sahin Antigen-specific t cell receptors and t cell epitopes
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
CN111693702A (zh) * 2020-07-11 2020-09-22 成都益安博生物技术有限公司 一种黑色素瘤的外周血tcr标志物及其检测试剂盒和应用
WO2022055946A1 (en) 2020-09-08 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
WO2022063965A1 (en) * 2020-09-24 2022-03-31 Medigene Immunotherapies Gmbh Mage-a3 specific t cell receptors and their use
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
EP4667056A1 (en) 2021-12-22 2025-12-24 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4456911A2 (en) 2021-12-31 2024-11-06 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
LT4245756T (lt) 2022-03-17 2024-11-25 Gilead Sciences, Inc. Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
CN120380014A (zh) * 2022-07-11 2025-07-25 得克萨斯州大学系统董事会 靶向vcy抗原的肽和经改造t细胞受体及使用方法
TW202417476A (zh) 2022-08-18 2024-05-01 英商英美偌科有限公司 Ｔ細胞受體及其融合蛋白
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
EP4695260A1 (en) 2023-04-11 2026-02-18 Gilead Sciences, Inc. Kras modulating compounds
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2024222701A1 (zh) * 2023-04-25 2024-10-31 苏州沙砾生物科技有限公司 一种t细胞受体及其用途
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
AU2024300557A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (pl) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2072356A1 (en) 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69333670T2 (de) * 1992-08-31 2005-03-10 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE272113T1 (de) 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19625191A1 (de) 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
IL127142A0 (en) * 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
CN1402782A (zh) * 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL2327763T3 (pl) * 2005-08-05 2018-08-31 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generowanie komórek T specyficznych względem antygenu
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
US7820174B2 (en) * 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
WO2008133772A1 (en) * 2007-04-26 2008-11-06 Ludwig Institute For Cancer Research Method for modulating activity of t lymphocytes
KR101363928B1 (ko) 2007-06-11 2014-02-19 고쿠리츠다이가쿠호진 미에다이가쿠 특이적 유전자 발현 방법
GB0720118D0 (en) 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8785601B2 (en) * 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2598528A1 (en) * 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
WO2012017081A1 (en) * 2010-08-06 2012-02-09 Ludwig-Maximilians-Universität München Identification of t cell target antigens
WO2012054825A1 (en) * 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
EP3392270B1 (en) 2011-09-15 2020-08-26 The United States of America, as Represented by the Secretary Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage

Also Published As

Publication number Publication date
CN103974974A (zh) 2014-08-06
IL290105B1 (en) 2023-12-01
JP6855426B2 (ja) 2021-04-07
SI3392270T1 (sl) 2020-12-31
AU2017204103A1 (en) 2017-07-06
EP2755997B1 (en) 2018-07-04
EP2755997A1 (en) 2014-07-23
AU2012309830B2 (en) 2017-03-30
PT3392270T (pt) 2020-11-24
CN109517055A (zh) 2019-03-26
EP3392270B1 (en) 2020-08-26
US20260001930A1 (en) 2026-01-01
IL290105B2 (en) 2024-04-01
PL3392270T3 (pl) 2021-03-08
IL268157A (en) 2019-09-26
WO2013039889A1 (en) 2013-03-21
US11306131B2 (en) 2022-04-19
JP7149364B2 (ja) 2022-10-06
EP3392270A1 (en) 2018-10-24
CA2848209A1 (en) 2013-03-21
SI2755997T1 (sl) 2018-11-30
CN109517055B (zh) 2022-09-20
JP2014528714A (ja) 2014-10-30
IL231323A0 (en) 2014-04-30
PT2755997T (pt) 2018-10-30
US20220195008A1 (en) 2022-06-23
AU2012309830A1 (en) 2014-03-27
JP2021100948A (ja) 2021-07-08
IL231323B (en) 2019-08-29
US20140378389A1 (en) 2014-12-25
EP3766896A1 (en) 2021-01-20
US20190016777A1 (en) 2019-01-17
CA3114877C (en) 2023-09-12
CA3114877A1 (en) 2013-03-21
IL268157B (en) 2021-04-29
CA2848209C (en) 2021-06-01
US12441778B2 (en) 2025-10-14
ES2834070T3 (es) 2021-06-16
AU2017204103B2 (en) 2019-03-07
EP3766896B1 (en) 2025-11-05
JP6415322B2 (ja) 2018-10-31
JP2019037232A (ja) 2019-03-14
IL290105A (en) 2022-03-01
IL281806B (en) 2022-03-01
ES2689512T3 (es) 2018-11-14
IL281806A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
PL2755997T3 (pl) Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7
IL237560A0 (en) T cell receptors recognizing mhc class ii-restricted mage-a3
IL232257A0 (en) Personal aircraft
PL2749012T3 (pl) Etui wodoodporne
DK2909807T3 (da) Forbedringer i forhold til undervandsbilleddannelse til undervandsundersøgelser
BR112014010035A8 (pt) mochila para transportar água
FI20115270L (fi) Lentolaite
EP2725663A4 (en) CONNECTOR
EP2758058A4 (en) SUBSTITUTED PYRIMIDINES
BR112013030248A2 (pt) aeronave
EP2758059A4 (en) SUBSTITUTED PYRIMIDINES
BR112014004742A2 (pt) calheira
BR112013032213A2 (pt) cocho independente
EP2763255A4 (en) Connector
EP2776543A4 (en) LUBRICANT COMPOSITION
ES1078886Y (es) Labio para excavadora
FR2997974B1 (fr) Sanitaires combines
EP2766227A4 (en) CAMERA ARRANGEMENT
FI20116108L (fi) Voitelujärjestely
FI20110263L (fi) Jaettava kahvakuula
ES1075920Y (es) Cabina de sufragio
UA22573S (uk) Костюм для пожежників
EE01140U1 (et) Astelpajunaps
FI20115682A0 (fi) 3D integraatio
ES1074688Y (es) Mochila